Notícias e Atividades da PepGen

PepGen é uma empresa listada sob o símbolo PEPG (US).

Veja o organograma con seus 23 executivos principais

Biografias mais buscadas da PepGen

• James McArthur, Chief Executive Officer and Executive Board Member
• Habib Dable, Director
• Josh Resnick, Non-Executive Director

Recentes movimentos de executivos em PepGen

• Patricia Fraser, Vice President, Pharmacovigilance, deixou a Companhia  (Notícia publicada em 9 de dezembro de 2025).
• Joseph Vittiglio, ingressou na Companhia como Chief Business and Legal Officer  (Notícia publicada em 8 de dezembro de 2025).

Criar um alerta
para seguir os movimentos de executivos da PepGen.

PepGen possui 3.493 concorrentes concorrentes UnitedHealth Group (Estados Unidos), Kaiser Permanente (Estados Unidos) e HCA (Estados Unidos).

Popular M&A news in Saúde

• Hims & Hers adquiriu Eucalyptus (publicado em 2 de junho de 2026).
• Freeman Health System adquiriu Northwest Health (publicado em 2 de junho de 2026).
• Garner Health acaba de anunciar uma arrecadação de fundos de 100 milhões de dólares. (publicado em 29 de maio de 2026).

Outros contatos sugeridos na indústria do Saúde

• Ari Bousbib - Chairman and Chief Executive Officer da IQVIA
• Gregory Adams - Chief Executive Officer and Chairman of the Board da Kaiser Permanente
• Pablo Legorreta - Chairman of the Board, Founder and Chief Executive Officer da Royalty Pharma

Saiba mais sobre a indústria do Saúde

Últimos comunicados de imprensa de PepGen

• PepGen Announces Appointment of Howard Mayer, M.D. to Board of Directors | PepGen
• News Releases | PepGen
• PepGen Reports Third Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
• Scientific Publications | PepGen
• PepGen Inc. Announces FDA has Lifted the Clinical Hold on its Investigational New Drug Application for FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 for Myotonic Dystrophy Type 1 (DM1) | PepGen
• PepGen Announces Upcoming Presentations at the 28th Annual Congress of the World Muscle Society | PepGen
• PepGen Inc. Announces Clearance of CTA by Health Canada to Begin the FREEDOM-DM1 Phase 1 Study of PGN-EDODM1 in Patients with Myotonic Dystrophy Type 1 | PepGen
• PepGen Inc. Presents PGN-EDODM1 Preclinical Data Supporting the Company’s Enhanced Delivery Oligonucleotide Platform and PGN-EDODM1 Program at Two Medical Conferences | PepGen
• PepGen Announces Presentations at the 2023 Myotonic Dystrophy Foundation Annual Conference, Ottawa Neuromuscular Disease Meeting, and H.C. Wainwright 25th Annual Global Investment Conference | PepGen
• PepGen Reports Second Quarter 2023 Financial Results and Recent Corporate Developments | PepGen
• View more press releases Close

Redes sociais sobre PepGen

• PepGen na Wikipedia, Google News e Yahoo Finance
• PepGen na LinkedIn, X (Twitter) e YouTube